Beyond Expedited Review: What Does FDA’s AMT Designation Program Actually Offer Sponsors?

Key Takeaways

The FDA’s Advanced Manufacturing Technology (AMT) Designation Program, established under Section 506L of the FD&C Act, provides a framework for requesting designation of novel manufacturing methods that substantially improve the manufacturing process while maintaining equivalent or superior drug quality, including by reducing development time or increasing or maintaining supply of critical or shortage-listed drugs. Windshire believes the program’s incentives are more targeted than many high-level commentaries imply and understanding where the value is concentrated matters before committing resources to a designation request.

The most immediate actionable benefit is access to early and additional interactions with the FDA, supported by a designated lead for AMT-related questions throughout the review process. Beyond early interaction, the program offers cross-application data referencing, prioritized FDA engagement for technologies tied to shortage risk, and a commercial credibility signal as technologies graduate from the program and gain broader industry acceptance. The FDA’s early implementation data suggest the program is active but selective. As of October 16, 2025, the FDA reported 18 designation requests, 3 granted designations, and 9 requests under active review.

Expanded Analysis

Understanding the novelty threshold

One eligibility question that sponsors may underestimate is what the FDA means by “novel.” The final December 2024 guidance clarified that a technology is considered novel when the FDA has limited assessment or inspectional experience with it. That may include a technology not previously submitted to the FDA, or an established technology proposed for use in a significantly different context. This is more flexible than a never-before-used standard. An established technique from another industry, applied for the first time in pharmaceutical manufacturing, can qualify, provided the applicant can demonstrate that it meets the program’s process maturity requirements. To meet those requirements, the applicant must be able to demonstrate through process development data that the technology consistently and reliably produces product meeting quality specifications within the proposed context of use. Proof-of-concept work alone will not satisfy this requirement.

Getting the context of use definition right at the outset is critical because the designation is granted at the technology level within a specified context rather than for a particular product, and an overly narrow or overly broad context can significantly affect the downstream utility of the designation.

Sponsors should also note that this requirement distinguishes the AMT program from the Emerging Technology Program, which is designed for earlier-stage development. AMT designation is not a tool for resolving early feasibility questions, and submitting prematurely risks denial and the reputational cost of a failed request.

The technology-level designation and what it unlocks

A distinctive structural feature of the AMT program is that designation is granted at the technology level, independent of any specific drug application. Contract manufacturers, technology developers, and platform technology holders can request designation without being the applicant for a particular product. Once granted, any authorized party can reference or rely upon the designation data in subsequent applications for drugs manufactured using that technology within the same context of use.

For sponsors and technology developers working across multiple products, this has meaningful practical implications. The same AMT foundation may not need to be re-established from scratch in each application. A developer of a continuous manufacturing platform for solid oral dosage forms, for example, could establish the regulatory foundation once and extend it across multiple NDA products by authorized parties referencing the designation.

Sponsors whose products are subject to BLA approval should note that the cross-referencing mechanism may operate differently because of existing limitations on BLA reliance on master files. In practice, biologics sponsors may need to evaluate early what information must be included directly in the BLA, what may be cross-referenced, and what data access rights will be needed. We encourage biologics sponsors to reach out for guidance on how these considerations apply to their development program before committing resources to a designation request.

What expedited assessment does, and does not, provide

The program provides expedited development and assessment of applications referencing a designated AMT, and that language appears in both the statute and the final guidance. However, CMC professionals familiar with Fast Track, Breakthrough Therapy, or Regenerative Medicine Advanced Therapy RMAT designations should understand that the AMT program’s expedited assessment is not as robust as those other programs. No specific additional meetings are guaranteed, no formal Prescription Drug User Fee Act (PDUFA) review clock is affected, and the guidance conditions additional interactions on FDA resources being available.

The final guidance also clarifies that an expedited assessment under the AMT program does not refer to an expedited user fee review goal. The degree of prioritization an application receives may also be affected by whether it has already been accepted into one of the established expedited programs. Sponsors whose technology squarely addresses shortage risk are better positioned to realize the expedited assessment benefit in practice than those pursuing designation on quality-improvement grounds alone.

Early and additional FDA interactions as the core practical benefit

The AMT program provides for early and additional interactions with the FDA, supported by a designated lead for AMT-related questions. This is where most sponsors will find the most concrete near-term value, but it requires deliberate preparation to use well. The program is best suited to resolving novel technical and regulatory questions related to manufacturing controls, process analytical technology, and validation strategy before those questions appear as deficiencies in a formal submission.

FDA’s Emerging Technology Team (ETT) and CBER’s Advanced Technologies Team (CATT) are separate, related programs whose staff may be involved in AMT-related discussions where applicable. ETT and CATT engagement in particular remains valuable for technologies in active development, but sponsors should understand that the interaction benefits of AMT designation are not contingent on ETT or CATT early involvement. The final December 2024 guidance removed the earlier draft requirement that sponsors engage with ETT or CATT as a prerequisite for submitting a designation request. Sponsors with technologies already at commercial-scale readiness may find it appropriate to proceed directly to a designation request.

In our experience, sponsors who arrive at FDA interactions with well-developed process understanding and specific, bounded questions tend to get substantially more actionable guidance than those using early meetings to explore whether a technology direction is viable at all.

Graduation and what it signals

Once a designated technology has been used in multiple approved applications and the FDA has accumulated sufficient assessment experience with it, the agency may graduate the technology from the AMT program and return future applications referencing it to the standard quality assessment process. Graduation ends the prioritized treatment and may also carry commercial significance. It signals to partners, licensees, and customers that the technology has moved from novel to established, supported by the FDA’s accumulated assessment experience, which has competitive value for technology developers and contract manufacturers that built their market position around early designation.

Sponsors considering AMT designation for platform technologies should factor the graduation lifecycle into their long-term regulatory strategy, particularly if the designation is expected to support partner applications over an extended period. The criteria and timing for graduation are not yet fully defined, and sponsors should raise this question directly with FDA during designation discussions.

Facing questions about AMT designation strategies, or broader drug development challenges? Contact our team at info@windshire.com or +1 844-686-5750 for expert guidance.

Below are some frequent questions we run into.

Frequently Asked Questions

Can a contract manufacturer or technology developer submit a designation request without being the drug applicant?

Yes, and this is one of the more practically significant features of the program. Designation requests are independent of any specific drug application, meaning contract manufacturers and technology developers can pursue designation for a manufacturing method without being the sponsor of a particular product. The benefits of the designation are realized, however, only when an authorized party references the designated technology in an appropriate application within the granted context of use. Sponsors considering this route should establish clear contractual arrangements governing who holds the designation and how data referencing rights are extended to applicants.

Is early engagement with the FDA required before submitting a designation request?

No. The final December 2024 guidance removed the draft requirement that sponsors engage with CDER’s Emerging Technology Team or CBER’s Advanced Technologies Team as a prerequisite. Early engagement with the FDA through the AMT program’s own interaction framework remains strongly recommended for technologies still in active development, because it allows manufacturing control and validation questions to be resolved before they appear as deficiencies in a formal submission. For technologies already at or near commercial-scale readiness, it may be appropriate to proceed directly to a designation request.

How does the AMT designation interact with other expedited programs such as Fast Track or Breakthrough Therapy?

The programs are not mutually exclusive, but sponsors should understand that holding an AMT designation does not, in and of itself, trigger the meeting commitments or review clock protections associated with those programs. The final guidance notes that the degree of prioritization an AMT-designated application receives may be affected by whether it has also been accepted into one of the established expedited programs. Sponsors with products that qualify for both should carefully consider how to sequence and coordinate those interactions with the FDA rather than treating them as independent tracks.

What happens to a designation once the technology becomes widely adopted?

FDA may graduate a technology from the AMT program once it has been used in multiple approved applications and the agency has accumulated sufficient assessment experience with it. Graduation returns future applications referencing that technology to the standard quality assessment process. For technology developers whose commercial strategy depends on designation-supported partner applications over an extended period, graduation timelines should be factored into long-term regulatory planning. The criteria and timing for graduation are not yet fully defined, and sponsors should raise this question directly with the FDA during designation discussions.

Does the designation apply to active pharmaceutical ingredient manufacturing as well as finished dosage form?

Yes. The program covers manufacturing methods for drugs, including biological products and their active pharmaceutical ingredients. Sponsors developing novel API manufacturing approaches, including those using continuous processing or innovative synthetic methods, should evaluate eligibility on the same statutory criteria as finished dosage form technologies.

What is the timeline for FDA’s review of a designation request, and is there a deadline for submitting one?

The FDA is required by statute to complete its review and issue a written determination on a designation request within 180 calendar days of receipt. Requests that are incomplete or do not meet the criteria established in Section 506L(b) of the FD&C Act will be denied, though a denied request may be resubmitted if additional supporting data and information become available. Sponsors should also be aware that Section 506L contains a sunset provision: FDA may not consider any designation requests submitted after October 1, 2032. For organizations evaluating advanced manufacturing investments with long development timelines, this deadline has direct strategic implications. A technology that requires several more years of process development before it can support a credible designation request may have a narrower window than it appears, particularly if graduation timelines and partner application cycles are factored in. We encourage sponsors with technologies in earlier stages of development to map their anticipated readiness against the 2032 cutoff as part of their regulatory planning.